Abstract

Immunocompromised individuals are at high risk of developing Clostridium difficile-associated disease (CDAD). Fecal microbiota transplantation (FMT) is a highly effective therapy for refractory or recurrent CDAD and, despite safety concerns, has recently been offered to immunocompromised patients. We investigated the genomics of bacterial composition following FMT in immunocompromised patients over a 1-year period. Metagenomic, strain and gene-level bacterial dynamics were characterized in two CDAD-affected hematopoietic stem cell (HCT) recipients following FMT. We found alterations in gene content, including loss of virulence and antibiotic resistance genes. These alterations were accompanied by long-term bacterial divergence at the species and strain levels. Our findings suggest limited durability of the specific bacterial consortium introduced with FMT and indicate that alterations of the functional potential of the microbiome are more complex than can be inferred by taxonomic information alone. Our observation that FMT alone cannot induce long-term donor-like alterations of the microbiota of HCT recipients suggests that FMT cannot indefinitely supersede environmental and/or host factors in shaping bacterial composition.

Highlights

  • Fecal microbiota transplantation (FMT) is a remarkably safe and effective therapy for resolving recurrent Clostridium difficile-associated disease (CDAD) in immunocompetent individuals [1], and it is increasingly being used to treat CDAD in immunocompromised individuals [2]

  • FMT is typically performed in patients with CDAD after significant clinical improvement is achieved with antimicrobial therapy

  • Our study provides one of the first metagenomic analysis of strain- and gene-level bacterial engraftment following FMT, and the first such analysis in patients being treated for CDAD

Read more

Summary

Introduction

Fecal microbiota transplantation (FMT) is a remarkably safe and effective therapy for resolving recurrent Clostridium difficile-associated disease (CDAD) in immunocompetent individuals [1], and it is increasingly being used to treat CDAD in immunocompromised individuals [2]. Manasevit (National Marrow Donor Program (bethematch.org)) award to ASB; National Cancer Institute (cancer.gov) K08 CA184420 to ASB., and the Thomas C. and Joan M. Merigan Endowment at Stanford University to DAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.